MedTrace Logo

BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status

NCT00779064 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2014-12-25

No results posted yet for this study

Summary

This is a clinical study investigating pharmacokinetics, pharmacodynamic effects and safety of BAY 59-7939 in patients with atrial fibrillation (originally described in Japanese).

Conditions

Interventions

DRUG

Rivaroxaban (BAY59-7939)

10mg BID, Semi-sequential, dose escalation.

DRUG

Rivaroxaban (BAY59-7939)

20mg BID, Semi-sequential, dose escalation.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00779064 on ClinicalTrials.gov